M3 Research Institute Releases Report on COVID-19 Treatment Disparities Across Japan

Insights from M3's COVID-19 Treatment Report

M3 Research Institute, established by M3 Inc. in Tokyo, unveiled a comprehensive report earlier today, titled 'COVID-19 Treatment Disparities Study.' This document employs unique real-world data to examine the treatment landscape for COVID-19 in Japan, with special emphasis on regional differences in the prescription rates of oral antiviral medications.

Background and Objectives

M3 Inc. has a mission aimed at promoting healthy, long-lived individuals while also minimizing unnecessary medical expenses through internet utilization. The establishment of M3 Research Institute in 2024 aimed to leverage the extensive network of healthcare professionals and vast medical big data available to conduct neutral surveys and research about Japan's healthcare realities. In light of the ongoing COVID-19 pandemic—which has persisted despite a gradual normalization of social activities—this research holds particular importance. As new infection rates have begun to rise again after the summer of 2025, the urgency for suitable treatment to avoid severe health outcomes has increased.

In response to these changing dynamics, the M3 Research Institute aspired to develop an insightful resource for healthcare professionals and local governments by meticulously analyzing prescription rates for antiviral drugs across different regions. The report's findings aim to assist medical experts and policymakers as they navigate future strategies to combat COVID-19.

Report Overview

- Title: COVID-19 Treatment Disparities Study
- Release Date: August 7, 2025
- Access: Available via M3 press release
- Content: The report encompasses an analysis of real-world data reflecting the current COVID-19 treatment practices and particularly focuses on the disparities in antiviral drug prescriptions across different regions in Japan. It also includes a survey targeting physicians, offering a multi-faceted perspective on the background of regional differences in COVID-19 treatment and physicians' needs.

Analysis Characteristics

- High Reliability Utilizing Real-World Medical Data: The report is founded on one of the largest medical databases in Japan, JAMDAS®︎, ensuring a high standard of reliability.
- Multi-Faceted Analysis Combining Treatment Reality and Physician Insights: By integrating prescription rate disparities drawn from real-world data with survey results from m3.com physician members, the report achieves a thorough analysis. This comprehensive approach has illuminated possible factors contributing to regional differences in antiviral drug prescriptions for COVID-19, as well as future physician requirements in the treatment of the disease.

This initiative represents a pivotal opportunity to harness insights from healthcare big data to address societal challenges, generating new social impacts. The institute is committed to continuing its analytical endeavors across various medical conditions and contributing significantly to the resolution of challenges facing Japan's healthcare system.